66 results
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure
8-K
EX-1.1
SEEL
Seelos Therapeutics Inc
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, post
424B5
7e24zaj62 supn
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
x6lr021be
28 Nov 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-10.1
on7anzqc kuhujsbpa
25 Sep 23
Entry into a Material Definitive Agreement
4:06pm
424B5
ncolztdm7 mhkgbkdx
25 Sep 23
Prospectus supplement for primary offering
6:02am
424B5
d4yfupu
12 May 22
Prospectus supplement for primary offering
8:30am
8-K
EX-10.1
h3y3 rx09xn
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am